Advertisement

Antibodies for Inflammatory Disease

Cytokines
  • Peter C. Taylor
Part of the Methods in Molecular Medicine book series (MIMM, volume 40)

Abstract

Cytokines are small proteins and major mediators of local intercellular communication required for an integrated response to a variety of stimuli in immune and inflammatory responses. By binding their cognate receptors on target cells, these short-lived molecules play a role in many important biological processes, including cell proliferation, activation, death, and differentiation. During an inflammatory response many cytokines are synthesized by a wide range of cell types, including leukocytes and fibroblasts. Some cytokines are proinflammatory, such as interleukin-1 (IL-1) and tumor necrosis factor a (TNF-α); others, such as interleukin-10 (IL-10) and transforming growth factor β(TGF-β), exert predominantly anti-inflammatory effects. However, it is now understood that many cytokines, for example, interferon-γ (IFN-γ), with chiefly proinflammatory activity, can also in some instances have anti-inflammatory properties. Similarly, cytokines with predominantly anti-inflammatory activity, such as IL-10 and TGF-β may also exhibit proinflammatory properties and therefore have pathogenic potential. Paracrine or autocrine pathways involving cytokines with either pro- or anti-inflammatory activity can lead to reverberating networks determining whether chronic inflammation results.

Keywords

Rheumatoid Arthritis Rheumatoid Arthritis Patient Cerebral Malaria Antibody Treatment Swell Joint Count 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, H., and Woody, J. N. (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105–1110.CrossRefPubMedGoogle Scholar
  2. 2.
    Pincus, T. and Callahan, L. F. (1993) What is the natural history of rheumatoid arthritis? Rheum. Dis. Clin. North Am. 19, 123–151.PubMedGoogle Scholar
  3. 3.
    Sharp, J. T., Wolfe, F., Mitchell, D. M., and Bloch, D. A. (1991) The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum. 34, 660–668.CrossRefPubMedGoogle Scholar
  4. 4.
    Janossy, G., Panayi, G., Duke, O., Bofill, M., Poulter, L. W., and Goldstein, G. (1981) Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immuno-regulation. Lancet ii, 839–841.CrossRefGoogle Scholar
  5. 5.
    Cush, J. J. and Lipsky, P. E. (1988) Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum. 31, 1230–1238.CrossRefPubMedGoogle Scholar
  6. 6.
    Firestein, G. S. and Zvaifler, N. J. (1990) How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 33, 768–773.CrossRefPubMedGoogle Scholar
  7. 7.
    Miossec, P., Naviliat, M., D’Angeac, A. D., Sany, J., and Banchereau, J. (1990) Low levels of interleukin-4 and high levels of transforming growth factor β in rheumatoid synovitis. Arthritis Rheum. 33, 1180–1187.CrossRefPubMedGoogle Scholar
  8. 8.
    Feldmann, M., Brennan, F. M., and Maini, R. N. (1996) Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 14, 397–440.CrossRefGoogle Scholar
  9. 9.
    Buchan, G., Barrett, K., Turner, M., Chantry, D., Maini, R. N., and Feldmann, M. (1988) Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-lα. Clin. Exp. Immunol. 73, 449–455.PubMedGoogle Scholar
  10. 10.
    Brennan F. M., Chantry, D., Jackson, A., Maini R., and Feldmann, M. (1989) Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244–247.CrossRefPubMedGoogle Scholar
  11. 11.
    Butler, D., Maini, R. N., Feldmann, M., and Brennan, F. M. (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TFN-alpha antibody with the interleukin-1 receptorantagonist. Eur. Cytokine Netw. 6(4), 225–230.PubMedGoogle Scholar
  12. 12.
    Dayer, J. M., Beutler, B., and Cerami, A. (1985) Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 162, 2163–2168.CrossRefPubMedGoogle Scholar
  13. 13.
    Katsikis, P. D., Chu, C. Q., Brennan, F. M., Maini, R. N., and Feldmann, M. (1994) Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J. Exp. Med. 179, 1517–1527.CrossRefPubMedGoogle Scholar
  14. 14.
    Fava, R., Olsen, N., Keski-Oja, J., Moses, H., and Pincus, T. (1989) Active and latent forms of transforming growth factor β activity in synovial effusions. J. Exp. Med. 169, 291–296.CrossRefPubMedGoogle Scholar
  15. 15.
    Wahl, S. M. (1994) Transforming growth factor β: The good, the bad, and the ugly. J. Exp. Med. 180, 1587–1590.CrossRefPubMedGoogle Scholar
  16. 16.
    Cope, A. P., Aderka, D., Doherty, M., Engelmann, H., Gibbons, D., Jones, A. C., Brennan, F. M., Maini, R. N., Wallach, D., and Feldmann, M. (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatoid diseases. Arthritis Rheum. 35, 1160–1169.CrossRefPubMedGoogle Scholar
  17. 17.
    Coley, W. (1893) The treatment of malignant tumours by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105, 487–511.CrossRefGoogle Scholar
  18. 18.
    Aggarwal, B. B., Kohr, W. J., Hass, P. E., Moffat, B., Spencer, S. A., Henzel, W. J., Bringman, T. S., Nedwin, G. E., Goeddel, D. V., and Harkins, R. N. (1985) Human tumor necrosis factor. Production, purification, and characterization. J. Biol. Chem. 260, 2345–2354.PubMedGoogle Scholar
  19. 19.
    Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P.H., Derynck, R., Palladino, M. A., Kohr, W. J., Aggarwal, B. B., and Goeddel, D. V. (1984) Human tumor necrosis factor: precursor structure expression and homology to lymphotoxin. Nature 312, 724–729.CrossRefPubMedGoogle Scholar
  20. 20.
    Shirai, T., Yamaguchi, H., Ito, H., Todd, C. W., and Wallace, R. B. (1985) Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature 313, 803–809.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang, A. M., Creasey, A. A., Ladner, M. B., Lin, L. S., Strickler, J., Van Arsdell, J. N., Yamamoto, R., and Mark, D. F. (1985) Molecular clongin of the comple-mentary DNA for human tumor necrosis factor. Science, 228, 149–154.CrossRefPubMedGoogle Scholar
  22. 22.
    Beutler, B. and Cerami, A. (1986) Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 320, 584–588.CrossRefPubMedGoogle Scholar
  23. 23.
    Jones, E. Y., Stuart, D. I., and Walker, N. P. C. (1989) Structure of tumour necrosis factor. Nature 338, 225–228.CrossRefPubMedGoogle Scholar
  24. 24.
    Bazzoni, F. and Beutler, B. (1996) The tumor necrosis factor ligand and receptor families (review). N. Engl. J. Med. 334, 1717–1725.CrossRefPubMedGoogle Scholar
  25. 25.
    Engelmann, H., Aderka, D., Rubinstein, M., Rotman, D., and Wallach, D. (1989) A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 264, 11,974–11,980.PubMedGoogle Scholar
  26. 26.
    Seckinger, P., Isaaz, S., and Dayer, J. M. (1988) A human inhibitor of tumor necrosis factor a. J. Exp. Med. 167, 1511–1516.CrossRefPubMedGoogle Scholar
  27. 27.
    Poltorak, A., Peppel, K., and Beutler, B. (1994) Receptor-mediated label-transfer assay (RELAY): a novel method for the detection of plasma tumor necrosis factor at attomolar concentrations. J. Immunol. Methods 169, 93–99.CrossRefPubMedGoogle Scholar
  28. 28.
    Tracey, K. J. and Cerami, A. (1994) Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann. Rev. Med. 45, 491–503.CrossRefPubMedGoogle Scholar
  29. 29.
    Negussie, Y., Remick, D. G., DeForge, L. E., Kunkel, S. L., Eynon, A, and Griffin, G. E. (1992) Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer reaction of relapsing fever. J. Exp. Med. 175, 1207–1212.CrossRefPubMedGoogle Scholar
  30. 30.
    Chatenoud, L., Ferran, C., Reuter, A., Legendre, C., Gevaert, Y., Kreis, H., Franchimont, P., and Bach, J. F. (1989) Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N. Engl. J. Med. 320, 1420,1421.Google Scholar
  31. 31.
    Dayer, J. M. and Burger, D (1994) Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur. Cytokine Netw. 5, 563–571.PubMedGoogle Scholar
  32. 32.
    Marchant, A., Bruyns, C., Vanderabeele, P., Ducarme, M., Gerard, C., Delvaux, A., De Groote, D., Abramowicz, D., Velu, T., and Goldman, M. (1994) Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur. J. Immunol. 24, 1167–1171.CrossRefPubMedGoogle Scholar
  33. 33.
    Espevik, T., Figari, I. S., Shalaby, M. R., Lackides, G. A., Lewis, G. D., Shepard, H. M., and Palladino, M. A. J. (1987) Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J. Exp. Med. 166, 571–576.CrossRefPubMedGoogle Scholar
  34. 34.
    Han, J., Thompson, P., and Beutler, B. (1990) Dexamethasone and pentoxifylline inhibit endotoxin induced TNF synthesis at separate points in their signaling pathway. J. Exp. Med. 172, 391–394.CrossRefPubMedGoogle Scholar
  35. 35.
    Parmely, M. J., Zhou, W. W., Edwards, C. K., Borcherding, D. R., Silverstein, R., and Morrison, D. C. (1993) Adenosine and a related cabocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J. Immunol. 151, 389–396.PubMedGoogle Scholar
  36. 36.
    Bouma, M. G., Stad, R. K., van den Wildenberg, F. A., and Buurman, W. A. (1994) Differential regulatory efffects of adenosine on cytokine release by activated human monocytes. J. Immunol. 153, 4159–4168.PubMedGoogle Scholar
  37. 37.
    Vannier, E., Miller, L. C., and Dinarello, C. A. (1991) Histamine suppressess gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors. J. Exp. Med. 174, 281–284.CrossRefPubMedGoogle Scholar
  38. 38.
    Florquin, S., Amraoui, Z., Dubois, C., Decuyper, J., and Goldman, M. (1994) The protective role of endogenously synthesized nitric oxide in staphylococcal entero-toxin B-induced shock in mice. J. Exp. Med. 180, 1153–1158.CrossRefPubMedGoogle Scholar
  39. 39.
    Eigler, A., Moeller, J., and Endres, S. (1995) Exogenous and endogenous nitric oxide attenuate tumor necrosis factor synthesis in the murine macrophage cell line RAW 264.7. J. Immunol. 154, 4048–4054.PubMedGoogle Scholar
  40. 40.
    Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., and Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177, 1675–1680.CrossRefPubMedGoogle Scholar
  41. 41.
    Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., and Kollias, G. (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025–4031.PubMedGoogle Scholar
  42. 42.
    Williams, R. O., Feldmann, M., and Maini, R. N. (1992) Anti-TNF ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89, 9784–9788.CrossRefPubMedGoogle Scholar
  43. 43.
    Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough, M., Scallon, B., Moore, A. M., Vilcek, J., Daddona, P., and Ghrayeb, J. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30, 1443–1453.CrossRefPubMedGoogle Scholar
  44. 44.
    Winter, G. and Harris, W. J. (1993) Humanized antibodies. Immunol. Today 14, 243–246.CrossRefPubMedGoogle Scholar
  45. 45.
    Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., and Woody, J. N. (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum. 36, 1681–1690.CrossRefPubMedGoogle Scholar
  46. 46.
    Paulus, H. E., Egger, M. J., Ward, J. R., Williams, H. J., and The Cooperative Systemic Studies of Rheumatic Diseases Group (1990) Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum. 33, 477–484.CrossRefPubMedGoogle Scholar
  47. 47.
    Feldmann, M., Elliott, M. J., Woody, J. N., and Maini, R. N. (1997) Anti-tumor necrosis factor-a therapy in rheumatoid arthritis. Adv. Immunol. 64, 283–350.CrossRefPubMedGoogle Scholar
  48. 48.
    Davis, D., Charles, P. J., Potter, A., Feldmann, M., Maini, R. N., and Elliott, M. J. (1997) Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor a. Br. J. Rheum. 36, 950–956.CrossRefGoogle Scholar
  49. 49.
    Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Bijl, H., and Woody, J. N. (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125–1128.CrossRefPubMedGoogle Scholar
  50. 50.
    Maini, R. N., Elliott, M. J., Brennan, F. M., Williams, R. O., Chu, C. Q., Paleolog, E., Charles, P. J., Taylor, P. C., and Feldmann, M. (1995) Monoclonal anti-TNFa antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev. 144, 195–223.CrossRefPubMedGoogle Scholar
  51. 51.
    Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MacFarlane, J. D., Antoni, C., Leeb, B., Elliott, M. J., Woody, J. N., Schaible, T. F., and Feldmann, M. (1997) Low dose methotrexate (MTX) suppresses anti-globulin responses and potentiates efficacy of a chimeric monoclonal anti-TNFa antibody (cA2) given repeatedly in rheumatoid arthritis (RA). Arthritis Rheum. 40, S126.Google Scholar
  52. 52.
    Rankin, E. C. C., Choy, E. H. S., Kassimos, D., Kingsley, G. H., Sopwith, S. M., Isenberg, D. A., and Panayi, G. S. (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34, 334–342.CrossRefPubMedGoogle Scholar
  53. 53.
    Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., Widmer, M. B., and Blosch, C. M. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141–147.CrossRefPubMedGoogle Scholar
  54. 54.
    Abraham, E., Wunderink, R., Silverman, H., Perl, T. M., Nasraway, S., Levy, H., Bone, R., Wenzel, R. P., Balk, R., Allred, R., et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis sydrome. A randomized, controlled, double-bline, multicenter, clinical trial. TNF-alpha mAb Sepsis Study Group. JAMA 273, 934–941.CrossRefPubMedGoogle Scholar
  55. 55.
    Fischer, C. J. Jr., Opal, S. M., Dhainaut, J.-F., Stephens, S., Zimmerman, J. L., Nightingale, P., Harris, S. J., Schein, R. M. H., Panacek, E. A., Vincent, J.-L., Foulke, G. E., Warren, E. L., Garrard, C., Park, G., Bodmer, M. W., Cohen, J., Van Der Linden, C., Cross, A. S., Sadoff, J. C., and The Cooperative Systemic Studies of Rheumatic Diseases Group (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Med. 21, 318–327.CrossRefGoogle Scholar
  56. 56.
    Reinhart, K., Wiegand-Lohnert, C., Grimminger, F., Kaul, M., Withington, S., Treacher, D., Eckart, J., Willatts, S., Bouza, C., Krausch, D., Stockenhuber, F., Eiselstein, J., Daum, L., and Kempeni, J. (1996) Assessment of the safety and efficacy of the antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit. Care Med. 24, 733–742.CrossRefPubMedGoogle Scholar
  57. 57.
    Fekade, D., Knox, K., Hussein, K., Melka, A., Lalloo, D. G., Coxon, R. E., and Warrell, D.A. (1996) Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N. Engl. J. Med. 335, 311–315.CrossRefPubMedGoogle Scholar
  58. 58.
    Van Dullemen, H. M., Van Deventer, S. J. H., Hommes, D. W., Bijl, H. A., Jansen, J., Tytgat, G. N. J., and Woody, J. (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129–135.CrossRefPubMedGoogle Scholar
  59. 59.
    McCabe, R. P., Woody, J. N., van Deventer, S., Targan, S. R., Mayer, L., van Hogezand, R., Rutgeerts, P., Hahauer, S. B., Podolsky, D., and Elson, C. O. (1996) A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease. Gastroenterology 110(Suppl.), A962.Google Scholar
  60. 60.
    Targan, S. R., Hanauer, S. B., van Deventer, S. J., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., and Rutgeerts, P. J. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Disease. N. Engl. J. Med. 337, 1029–1035.CrossRefPubMedGoogle Scholar
  61. 61.
    Stack, W. A., Mann, S. D., Roy, A. J., Heath, P., Sopwith, M., Freeman, J., Holmes, G., Long, R., Forbes, A., and Kamm, M. A. (1997) Randomised con-trolled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 349, 521–524.CrossRefPubMedGoogle Scholar
  62. 62.
    Charles, P., Potter, A., Elliott, M., Cope, A., Woody, J., Feldmann, M., and Maini, R. N. (1995) Regulation of sTNF-R and IL-6 following TNF blockade in RA: in vivo evidence for a cytokine cascade. Arthritis Rheum. 38, S342.Google Scholar
  63. 63.
    Tak, P. P., Taylor, P. C., Breedveld, F. C., Smeets, T. J. M., Daha, M. R., Kluin, P. M., Meinders, A. E., and Maini, R. N. (1996) Decrease in cellularity and expres-sion of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 39, 1077–1081.CrossRefPubMedGoogle Scholar
  64. 64.
    Taylor, P. C., Maini, R. N., Tak, P. P., Breedveld, F. C., Smeets, T. J. M., Daha, M. R., Kluin, P. M., and Meinders, A. E. (1997) Reply to Decrease in cell adhe-sion molecules by treatment with anti-tumor necrosis factor a monoclonal antibody. Arthritis Rheum. 4, 789–790.CrossRefGoogle Scholar
  65. 65.
    Gearing, A. J. H. and Newman, W. (1993) Circulating adhesion molecules in dis-ease. Immunol. Today 14, 506–512.CrossRefPubMedGoogle Scholar
  66. 66.
    Leeuwenberg, J. F. M., Smeets, E. F., Neefjes, J. J., Shaffer, M. A., Cinek, T., Jeunhomme, T. M. A. A., and Buurman, W. A. (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77, 543–549.Google Scholar
  67. 67.
    Paleolog, E. M., Elliott, M. J., Woody, J. N., Feldmann, M., and Maini, R. N. (1996) Deactivation of vascular endothelium by monoclonal anti-tumour necrosis factor a antibody in rheumatoid arthritis. Arthritis Rheum. 39, 1082–1091.CrossRefPubMedGoogle Scholar
  68. 68.
    Alvaro-Gracia, J. M., Zvaifler, N. J., Brown, C. B., Kaushansky, K., and Firestein, G. S. (1991) Cytokines in chronic inflammatory arthritis. J. Immunol. 146, 3365–3371.PubMedGoogle Scholar
  69. 69.
    Haworth, C., Brennan, F. M., Chantry, D., Turner, M., Maini, R. N., and Feldmann, M. (1991) Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α Eur. J. Immunol. 21, 2575–2579.CrossRefPubMedGoogle Scholar
  70. 70.
    Taylor, P. C., Chapman, P., Elliott, M. J., Schaible, T. F., Peter, A. M., Feldmann, M., and Maini, R. N. (1997) Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNFα therapy. Arthritis Rheum. 40, S80.CrossRefGoogle Scholar
  71. 71.
    Paleolog, E. M., Young, S., Stark, A. C., McCloskey, R. V., Feldmann, M., and Maini, R. N. (1998) Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis Rheum. 41, 1258–1265.CrossRefPubMedGoogle Scholar
  72. 72.
    Gay, S., Gay, R. E., and Koopman W. J. (1993) Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction? Ann. Rheum. Dis. 52, S39–S47.CrossRefPubMedGoogle Scholar
  73. 73.
    Vanlent, P. L. E. M., Vandeloo, F. A. J., Holthuysen, A. E. M., Vandenbersselaar, A. M., Vermeer, H., and Vandenberg, W. B. (1995) Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J. Rheumatol. 22, 2250–2258.Google Scholar
  74. 74.
    Brennan, F. M., Browne, K. A., Green, P. A., Jasper, J.-M., Maini, R. N., and Feldmann, M. (1997) Reduction of serum matrix metalloproteinase 1 and matrix: metalloproteinase 3 in RA patients following anti-TNFα (cA2) therapy. Br. J. Rheumatol. 36, 643–650.CrossRefPubMedGoogle Scholar
  75. 75.
    Wolfe, F., Mitchell, D. A., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., and Cathey, M. A. (1994) The mortality of rheumatoid arthritis. Arthritis Rheum. 37, 481–494.CrossRefPubMedGoogle Scholar
  76. 76.
    Williams, R. O., Mason, L. M., Feldmann, M., and Maini, R. (1994) Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 91, 2762–2766.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Peter C. Taylor
    • 1
  1. 1.The Mathilda and Terence Kennedy Institute of RheumatologyHammersmith HospitalLondonUK

Personalised recommendations